GABA-gated chloride channel Inhibitors
1 drugsAbout GABA-gated chloride channel
The GABA-gated chloride channel is a receptor activated by GABA, mediating inhibitory neurotransmission in the central nervous system. It allows chloride ions to flow into neurons, reducing their excitability and dampening neuronal signaling.
Currently, there is no genetic evidence directly linking GABA-gated chloride channels to specific diseases, limiting confidence in target validation.
One FDA-approved drug, XDEMVY, targets this channel as a small molecule therapeutic. TARSUS is the sole company with an approved drug in this space, with the therapeutic area classified as 'Other'.
Top GABA-gated chloride channel Drugs
TARSUS is the only company with an approved drug targeting GABA-gated chloride channels.
Low competition suggests easier market entry, but also highlights potential risks due to lack of established market.
GABA-gated chloride channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets GABA-gated chloride channel, using small molecule modality.
The absence of other modalities indicates a whitespace opportunity for novel approaches like antibodies or peptides.
GABA-gated chloride channel Clinical Trials 10 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on GABA-gated chloride channel. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 | 100% |
| Phase 2 | 3 | 1 | 0 | 2 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
GABA-gated chloride channel Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval was XDEMVY in 2023.
Recent entry indicates an emerging area, but also suggests potential for rapid saturation if more drugs follow.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on GABA-gated chloride channel. A trial counts if an approved drug acting on GABA-gated chloride channel is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.